Table 1. Patient characteristics and results

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| patients/Eye | Lateral | Age | Gender | Etiology | Duration of ME | best collected visual acuity (LogMAR) | central macular thickness (micrometer) | Previous treatment  |
| Baseline | 2-week | 6-week | baseline | 2-week | 6-week |
| 1/1 | OD | 74 | F | DME | 41 | 0.82 | 0.7 | 1 | 789 | 686 | 699 | 2IVB, 1STTA |
| 1/2 | OS | 74 | F | DME | 41 | 0.3 | 0.52 | 0.7 | 450 | 345 | 336 | 1STTA, vitrectomy |
| 2/3 | OS | 66 | M | BRVO | 58 | 0.52 | 0.7 | 0.52 | 633 | 561 | 609 | 6IVB |
| 3/4 | OS | 67 | M | BRVO | 27 | 0.3 | 0.22 | 0.22 | 408 | 332 | 389 | 1STTA, PC |
| 4/5 | OD | 77 | M | CRVO | 36 | 0.3 | 0.3 | 0.7 | 608 | 575 | 615 | 2IVB, 1IVA, 2STTA |
| 5/6 | OD | 52 | F | BRVO | 11 | 0.52 | 0.52 | 0.52 | 441 | 430 | 340 | 2IVR, 1IVA |
| 6/7 | OD | 66 | F | DME | 30 | 0.7 | 0.52 | 0.52 | 679 | 562 | 550 | 2IVR, 2IVA, 1STTA |
| 7/8 | OD | 64 | F | DME | 14 | 0.52 | 0.52 | 0.4 | 424 | 383 | 370 | 1STTA, PC |
| 8/9 | OS | 83 | M | BRVO | 11 | 0.15 | 0.15 | 0.05 | 344 | 309 | 356 | 2IVR |
| 9/10 | OS | 69 | F | DME | 44 | 0.3 | 0.3 | 0.15 | 334 | 330 | 315 | 3IVR, PC |
| 10/11 | OS | 72 | M | CRVO | 90 | 0.1 | 0.1 | 0.15 | 327 | 331 | 324 | 2IVB |
| 11/12 | OD | 74 | M | CRVO | 47 | 0.22 | 0.22 | 0.4 | 513 | 463 | 523 | 1IVB, 1IVR, 1IVA |
| 12/13 | OD | 47 | F | DME | 28 | 0.4 | 0.22 | 0.4 | 510 | 557 | 563 | 2STTA, PC, 1IVA |
| 12/14 | OS | 47 | F | DME | 28 | 0.52 | 0.52 | 0.52 | 673 | 671 | 627 | 3STTA, PC, 1IVA |
| Mean | 66.6 |  |  | 36.1 | 0.41 | 0.39 | 0.47 | 500.3 | 462.8 | 466.4 |  |
| (SD) | (11.0) |  |  | (20.8) | (0.21) | (0.20) | (0.26) | (144.8) | (129.4) | (134.4) |  |

ME, macular edema; LogMAR, logarithm of minimum angle of resolution; DME, diabetic macular edema; IVB, intravitreal injection of bevacizumab; STTA, sub-tenon injection of triamcinolone acetonide; BRVO, branch retinal vein occlusion; PC, photocoagulation; CRVO, central retinal vein occlusion; IVA, intravitreal injection of aflibercept; IVR, intravitreal injection of ranibizumab; SD, standard deviation